| 前收市價 | 5.27 |
| 開市 | 5.38 |
| 買盤 | 5.34 x 100 |
| 賣出價 | 5.36 x 100 |
| 今日波幅 | 5.30 - 5.70 |
| 52 週波幅 | 4.03 - 8.96 |
| 成交量 | |
| 平均成交量 | 3,381,419 |
| 市值 | 1.102B |
| Beta 值 (5 年，每月) | 1.93 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.07 |
| 業績公佈日 | 2024年8月01日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 14.00 |
Motley FoolWhy BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally.
BenzingaBioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
Monday, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a first-quarter earnings loss of $(0.17) per share versus the consensus estimate loss of $(0.21) per share and $(0.28) reported a year ago. BioCryst Pharma reported sales of $92.8 million, beating the consensus of $85.61 million. The sales increased 34.9% Y/Y, primarily due to $88.9 million in Orladeyo’s net revenue in the first quarter of 2024, up 30% Y/Y. “We are off to a fantastic start to the year with outstanding Orladeyo revenue g
Motley FoolBioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2024.
